Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

SOCRA CCRP Exam ACTUAL EXAM QUESTIONS & Verified ANSWERS WITH RATIONALES 2025 GRADED A+.pd, Exams of Nursing

SOCRA CCRP Exam ACTUAL EXAM QUESTIONS & Verified ANSWERS WITH RATIONALES 2025 GRADED A+.pdf

Typology: Exams

2024/2025

Available from 07/15/2025

Academicgenius
Academicgenius šŸ‡¬šŸ‡§

3.5

(22)

944 documents

1 / 18

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
SOCRA CCRP Exam ACTUAL EXAM QUESTIONS &
Verified ANSWERS WITH RATIONALES 2025 |GRADED
A+
When there is no additional relevant information to provide to the subject? - ANSWhen
is the informed consent process over?
Varied backgrounds, diversity and expertise
Upon earlier notification, investigations may begin - ANSHow long does it take for an
IND to go into effect? (21 CFR Part 312)
Uncontrolled (Long term expansion studies) - ANS5 Common Study Designs
Unapproved drug to be shipped lawfully for the purpose of conducting investigations of
the drug - ANSAn IND permits what? (21 CFR Part 312)
Unanticipated adverse device effect (UADE) - ANSWhat is the SAE counterpart in
device trials?
Triggered by NDA - ANSHow are study oriented FDA Inspections classified?
Triggered by data issue, complaint from study subject/staff, publication of results from
an ongoing study - ANSHow are investigator oriented FDA inspections classified?
To safeguard rights, safety and well being of all trial subjects
To pay special attention to trials that may include vulnerable subjects - ANSWhat are
the goals of an IRB? (21 CFR Part 56)
The subject only - ANS21 CFR Part 50 only requires who to sign the ICF?
The sponsor, the IRB evaluates the determination - ANSWho makes the initial
determination of SR or NSR?
the shipment of a device for the purpose of conducting investigations of the device
without complying without FDA requirements that would apply to devices in commercial
distribution - ANSWhat does an Investigational Device Exemption (IDE) permit?
The probability and magnitude of harm or discomfort anticipated in the research are not
greater in and of themselves than those ordinarily encountered in daily life or during the
performance of routine physical or psychological exams and tests - ANSIRB definition of
Minimal Risk
The Informed Consent Process - ANSWhen does the subject have the right to ask
questions about the study?
The Informed Consent Form - ANSWhat cannot include language that releases or
appears to release investigator, institution, sponsor or their agents from liability for
negligence?
The Informed Consent Form - ANSWhat cannot contain language that waives or
appears to waive the rights of the subject?
The FDA - ANSWho determines if Phase II/III studies are likely to yield data capable of
meeting regulatory standards for marketing approval?
temperature - ANSCore Battery for Central Nervous System
Table of Contents
surgical drapes - ANSExamples of Class II devices
Subjects may not be given the investigational drug - ANSWhat does a FDA "Clinical
Hold" mean for a proposed study?
pf3
pf4
pf5
pf8
pf9
pfa
pfd
pfe
pff
pf12

Partial preview of the text

Download SOCRA CCRP Exam ACTUAL EXAM QUESTIONS & Verified ANSWERS WITH RATIONALES 2025 GRADED A+.pd and more Exams Nursing in PDF only on Docsity!

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

When there is no additional relevant information to provide to the subject? - ANSWhen is the informed consent process over? Varied backgrounds, diversity and expertise Upon earlier notification, investigations may begin - ANSHow long does it take for an IND to go into effect? (21 CFR Part 312) Uncontrolled (Long term expansion studies) - ANS5 Common Study Designs Unapproved drug to be shipped lawfully for the purpose of conducting investigations of the drug - ANSAn IND permits what? (21 CFR Part 312) Unanticipated adverse device effect (UADE) - ANSWhat is the SAE counterpart in device trials? Triggered by NDA - ANSHow are study oriented FDA Inspections classified? Triggered by data issue, complaint from study subject/staff, publication of results from an ongoing study - ANSHow are investigator oriented FDA inspections classified? To safeguard rights, safety and well being of all trial subjects To pay special attention to trials that may include vulnerable subjects - ANSWhat are the goals of an IRB? (21 CFR Part 56) The subject only - ANS21 CFR Part 50 only requires who to sign the ICF? The sponsor, the IRB evaluates the determination - ANSWho makes the initial determination of SR or NSR? the shipment of a device for the purpose of conducting investigations of the device without complying without FDA requirements that would apply to devices in commercial distribution - ANSWhat does an Investigational Device Exemption (IDE) permit? The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological exams and tests - ANSIRB definition of Minimal Risk The Informed Consent Process - ANSWhen does the subject have the right to ask questions about the study? The Informed Consent Form - ANSWhat cannot include language that releases or appears to release investigator, institution, sponsor or their agents from liability for negligence? The Informed Consent Form - ANSWhat cannot contain language that waives or appears to waive the rights of the subject? The FDA - ANSWho determines if Phase II/III studies are likely to yield data capable of meeting regulatory standards for marketing approval? temperature - ANSCore Battery for Central Nervous System Table of Contents surgical drapes - ANSExamples of Class II devices Subjects may not be given the investigational drug - ANSWhat does a FDA "Clinical Hold" mean for a proposed study?

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Subject and person conducting the consent process - ANSICH E6 guidelines requires who to sign the ICF? Study that investigates the mode of action and/or effects of a drug substance in relation to its desired therapeutic target - ANSPrimary Pharmacodynamic Studies Study Oriented Studies that investigate the potential undesirable PD effects of a substance on physiological functions in relation to exposure in the therapeutic range or above - ANSSafety Pharmacology Studies (Pre-Clinical) Studies that investigate the mode of action and/or effects of a drug substance not related to its desire therapeutic target - ANSSecondary Pharmacodynamic Studies Sponsor Medical Monitor - ANSWho is responsible for clinical oversight, evaluating safety information-trial wide? Sponsor - ANSWho is responsible with providing pre-clinical and clinical study reports in the information amendments to the IND? Sponsor - ANSWho is responsible to terminate all studies if the product presents an unreasonable and significant risk to study subjects? Sponsor - ANSWho is responsible fore maintaining an effective IND or IDE? Sponsor - ANSWho is responsible for submitting safety reports to sites? Sponsor - ANSWho is responsible for selecting qualified monitors? Sponsor - ANSWho is responsible for selecting qualified investigators? Sponsor - ANSWho is responsible for promptly reporting information about significant new adverse events or unanticipated adverse device effect with respect to the investigational product? Sponsor - ANSWho is responsible for ensuring all investigators are conducting studies according to the general investigational plan and protocols in the IND? Sponsor - ANSWho is required to notify all parties involved, if warranted, of new safety information adversely affecting subject safety? Sponsor - ANSWho has the responsibility to obtain an agreement from the investigator to adhere to the protocol, obtain IRB approval and GCP compliance? Sponsor - ANSWho has the responsibility to ensure the study is designed by qualified individuals? Sponsor - ANSWho has the responsibility in submitting an annual report to the IND/IDE? Sponsor - ANSWho has the responsibility in maintaining quality assurance and quality control systems, with SOPs, for all activities? Sponosr - ANSWho is responsible for providing information needed to conduct the study?

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Powered wheel chairs Placebo controlled Pivotal Study - ANSTypes of Device Trials Pilot Study Phase III - ANSWhat phase of study usually has the largest number of subjects per study? Phase II/III - ANSWhat phases of stuides are usually multicenter? Phase II/ III trials or Phase II and III - ANSThese phase of trials, the FDA helps assure the quality of the scientific evaluation is adequate to permit evaluation of the drugs safety and efficacy ( CFR Part 312) Phase I - ANSWhat phase of study is usually single-center? pharm and tox information Parallel Group (efficacy and safety) On-Site Monitors - ANSWho is responsible for periodic site visits? no-treatment concurrent control Not less than once a year Non-significant risk trials - ANSWhat type of device studies are subject to abbreviated IDE regulations? (21 CFR Part 812.2b) No white-Out - ANSHow should source document corrections be made according to GCP guidelines? no new subjects may be given the IP and subjects already taking the drug should be discontinued unless continuation is specifically permitted by the FDA - ANSWhat does a FDA "Clinical Hold" mean for an ongoing study? No erasures New Drug Application - ANS21 CFR 314 Need for investigational drug arises in an emergency situation Multidisciplinary - ANSICH M Motor activity Monitor Responsibilties - ANSICH E6, Section 5. Moderate risk, usually requires 510k, might require PMA - ANSHow do you define a device with Class II risk? Medical Device Reporting - ANS21 CFR Part 803 Medical Device Classification Procedures - ANS21 CFR Part 860 Make study records available for inspection - ANS21 CFR Part 312. Maintain adequate and accurate records Lowest Risk, 510K often not required - ANSHow do you define Class I Devices? investigator's brochure Investigator responsibilitiy - ANS21 CFR Part 312. Investigator Responsibilities - ANSICH E6 Section 4 Investigator Responsibilities - ANS21 CFR 312.60- 70 Investigator Oriented - ANSWhat are the two types of FDA Inspections?

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Investigational New Drug Application Investigational Device Exemption - ANS21 CFR Part 812 Investigational Device Exemption - ANS21 CFR 812 Investigational agreement - ANSWhat is used in device studies instead of a 1572? Introductory statement Interventions designed solely to enhance well-being of the patient with reasonable expectation of success - ANSHow does the Belmont Report Define "Practice"? Insufficient time to allow for submission of an IND or a treatment IND Institutional Review Board - ANS21 CFR Part 56 Initial and date the change infusion pumps Informed consent - ANSWhat must be obtained from the subject or LAR prior to initiating any research related exams? Informed Consent - ANSICH E6 Section 4. Informed Consent - ANS21 CFR Part 50 IND Application - ANS21 CFR 312 implanted cerebella stimulators implantable pacemakeres - ANSExamples of Class III Drugs Immediately - ANSWhen do SAEs need to be reported to Sponsors? If the research is funded in whole or part by HHS and regulated by the FDA - ANSWhen is research regulated by both FDA and HHS? If the changes in the research trial affect the treatment of the subject, or may affect the subject's willingness to continue in the study - ANSWhen must patient's be reconsented? Identification and correction - ANSWhat does QC focus on? historical control - ANSWhat type of controls are commonly used in patient trials? Highest risk, PMA required - ANSHow do you define a device with Class III risk? HHS Regulations for Protection of Human Subjects - ANS45 CFR Part 46 Heart Rate Health and Human Services - ANSHow is HHS defined? guidance for industry, consolidated guideance - ANSICH E 6 General Investigational Plan Functional Assessments (tidal volume, hgb Oxygen saturation) - ANSCore Battery for Respiratory System Form 483 - ANSWhat is the FDA form for issuing summary of observations during an inspection? Form 482 - ANSWhat is the FDA Inspection Form? For Cause or Directed Financial Disclosures - ANS21 CFR Part 54 FDA - ANSBefore clinical trials can be initiated, an application containing the appropriate information must be submitted to regulatory authorities, in the USA this is called XXXX and submitted to the XXX (21 CFR Part 312)

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Blinding - ANSWhat is used to minimize potential subconscious bias in evaluating treatment response? behavioral changes Be supported by additional information such as animal studies and other human studies

  • ANSAmendments to IND with new or revised protocols (21 CFR Part 312) Assuring the safety and rights of subjects - ANSFDA's primary objective in all phases of development is... April 30 1 996 - ANSICH GCP Development Date Appropriate for the risk involved An order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation - ANSWhat is a "Clinical Hold" All amounts - ANSWhat is the $ reported amount for a financial disclosure for equity interest in the sponsor? All amounts - ANSWhat is the $ reported amount for a financial disclosure for proprietary interest in the test product? All amounts - ANSWhat is the $ reportable amount for a financial disclosure if the amount is based on study outcome? After all the clinical trials have been completed and the sponsor of the controlled clinical trial is actively pursuing marketing approval of the drug with due dilligence - ANSA treatment protocol or IND are usually found in what phase of trials? Adverse Event - ANSWhat is defined as any untoward medical occurrence occurring in a patient or clinical investigation subject who has been administered an investigational product, does not necessarily have a causal relationship to the treatment? Activity designed to rest a hypothesis, draw a conclusion to develop or contribute to generalized knowledge - ANSHow does the Belmont Report define "Research"? active-treatment concurrent control A Progress Report - ANSIn order to conduct a continuing review, IRBs require what document? 9)freedom to withdraw consent - ANSWhat did the Nuremberg code establish? 8)conducted by qualified individuals
  1. Supplemental studies if needed - ANSTypes of Non-Clinical Studies (Animal Trials)
  2. statement that participation is voluntary - ANSWhat 8 ICF elements are required by 21 CFR 50 7)Who to contact 7)Current CV of Investigators - ANSWhat documents need to be submitted to the IRB? 7)any new information since last review - ANSIRB Progress Reports should include what elements?
  3. Reproduction toxicity
  4. proper facilities and preparation 7 Calendar days - ANSUnexpected fatal or life-threating suspected adverse reactions must be reported by the sponsor in what time frame? 6th-8th - ANSRecommended language level of ICF

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

6)significant new finding statement - ANSWhat additional elements can be included in an ICF, but not required? 6)significant findings and corrective action - ANSWritten monitoring reports should include what elements? 6)humanitarian Benefits outweigh risk

  1. Information about payments/compensation to subjets
  2. Current risk/benefit assessment
  3. Compensation
  4. Carcinogenicity 5)summary of what information was reviewed 5)should not be conducted if death or disability will occur with a priori knowledge 5)Research results thus far 5)economically or educationally disadvantaged - ANSWhat populations are more likely to be a vulnerable subject? 5)consequences of subject's decision to withdraw 5)Available safety data
  5. Statement of record confidentiality
  6. listing of device types - ANSWhat are the general controls that provide reasonable assurance of safety for a device?
  7. It is not used as a diagnostic procedure without confirmation by a medically established diagnostic product - ANSDevices can be granted IDE if:
  8. Genotoxicity
  9. All pages are accounted for - ANSICF Monitoring Ensures what 5 things 5 Working Days, IRB and sponsor - ANSWhat time frame and to whom do sites have to report deviations from investigational plan in order to protect life or well being of patients on device trials? 5 Working Days (Sponsor and IRB) - ANSNotification time requirement for emergency use of investigational device 5 Working Days - ANSHow quickly must a site notify the IRB of an emergency use of investigational drug? (21 CFR Part 312) 5 - ANSWhat is the minimum member requirement for an IRB? 45 CFR Part 46 - ANSFederal Research 4)The IND does not contain sufficient information to assess risk to subjects - ANSGrounds for FDA Clinical Hold in Phase 1 Trials 4)Special tests like ECG, PFTs, etc - ANSWhat kind safety evaluations are present in protocol and are designed to protect study subjects? 4)Reason for withdrawals 4)otherwise presents a potential for serious risk to the health, safety, or welfare of a subject - ANSA Significant Risk (SR) Device Study is defined as: 4)mentally disabled

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

3)Maintain drug and device accountability records from manufacturing through use, return and destruction - ANSWhat are SPONSOR responsibilities with regard to IP? 3)Justice - ANSWhat are the three principles of the Belmont Report? 3)is of substantial importance in diagnosing, curing, mitigating or treating disease or other prevents impairment of human health 3)Investigator's brochure is misleading, inaccurate or materially incomplete 3)Handicapped 3)Does not require invasive sampling procedure 3)Control the use of investigational product - ANSWhat are three primary responsibility of investigators? 3)CNS - ANSThree vital organ considered highest priority 3)and IRB approved written summary of what is to be said to the participant or LAR 3)All drug returned to the sponsor or destroyed as directed by sponsor 3)additional costs

  1. the subject dated, and is correct
  2. Subject recruitment materials (ads)
  3. results in persistent or significant injury
  4. Repeated dose toxicity
  5. Proprietary interest in tested product
  6. post-market surveilance - ANSIn addition to general controls, Class II devices are also subject to these types of special controls
  7. On-site monitoring - ANSWhat are three types of monitoring the sponsor is responsible for?
  8. Number of withdrawals
  9. monitor's name
  10. Known of suspected risks
  11. GMPs
  12. Disapproval - ANSWhat are the 3 outcomes of IRB review?
  13. Clinical laboratory tests
  14. Benefits to the subjects or others
  15. Based on animal studies
  16. Assess overall therapeutic value - ANSGoals of Phase III trials
  17. Absorption, distribution, metabolism and excretion studies 3 years - ANSHow long does an IRB retain all relevant records after completion of a trial? 21 CFR Part 814 - ANSpre market approval of medical devices 2)To obtain additional data on the drug's safety and effectiveness - ANSThe purpose of Treatment Use of Investigational Drug (21 CFR Part 312) 2)Significant equity interest in sponsor 2)Respiratory 2)Reported trial data are accurate, complete, and verifiable from source documents 2)Protect the rights, safety, and welfare of subjects

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

2 )Life-threatening 2)is used in supporting or sustaining life 2)if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application 2)Extent the drug has been studied previously 2)diagnostic device complying with labeling requirements, testing is non-invasive 2)CV 2)Clinical investigators are not qualified 2)Benefit of research not restricted to those who can afford it

  1. To evaluate adverse PD and/or pathophysio effects of a substance observed in toxicology studies
  2. The protocol is clearly deficient in design to meet the stated objects - ANSGrounds for FDA Clinical Hold in Phase II/III Trials
  3. Summary
  4. subjects enter into research voluntarily and with adequate information - ANSWhat does "Respect for Persons" entail?
  5. subject signature is present in addition to the subject's namr
  6. Stopping all studies and notifying the investigators
  7. Single dose toxicity
  8. Providing the investigational product only to investigators participating in an investigation
  9. Protecting from harm
  10. Premarket notification 510k requirements
  11. Pregnant women, children
  12. PK and PD property, might be cross over design
  13. obtain short term safety - ANSGoals of Phase II Trials
  14. No comparable or satisfactory alternative drug/therapy is available to treat the stage of disease in the intended patient population - ANSA treatment protocol or IND may be filed if: ((21 CFR Part 312)
  15. Modifications needed
  16. mandatory performance standards
  17. ICF
  18. Fruitful results
  19. FDA approval required before the device can be legally marketed - ANSPre-Market Approval Requirements
  20. Establish long term efficacy and safety
  21. Dispensing and return information for each subject
  22. Description of risks/discomforts
  23. date of the visit
  24. Data Safety Monitoring Boards
  25. Continue to assess overall therapeutic value
  26. circumstances that might end trial

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

  1. Statement that includes the nature of the research, the purpose, duration, procedures and experimental procedures
  2. Special labeling requirements
  3. Signed 1572 or investigational agreement
  4. Risks to embryo or fetus
  5. Respecting decisions
  6. Respect for persons
  7. Required process of scientific review to ensure the reasonable safety and effectiveness of medical devices
  8. Protocol and amendments
  9. Prohibition against adulterated or misbranded devices
  10. Prisoners
  11. PK and toxicokinetic
  12. Novelty of drug
  13. Notifying the FDA
  14. Medical Monitor
  15. Manufacturing, packaging, labeling and coding of the investigational drug
  16. Inventory of product received by site, and date
  17. Initial Safety, dose escalation studies to determine MTD
  18. Initial demonstration of efficacy in subjects with the condition under investigation
  19. In an Implant
  20. Fatal
  21. Fairness, potential participants should be treated equally
  22. Confirmation of short term efficacy and safety
  23. Compensation affected by study outcome or in the form of equity interest in sponsor or compensation tied to sales
  24. Cardiovascular
  25. Are usually those that support or sustain human life
  26. Approval
  27. Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with a device
  28. All grounds related to holds in Phase 1 trials AND
  29. Address FDA requirements for additional information not in NDA
  30. Achieve their primary intended purpose through chemical action within the body
  31. A Short form Consent document 1 member with scientific expertise 1 member with nonscientific concern 1 member not affiliated with insitution - ANSHow should an IRB be comprised?

$50,000 - ANSWhat is the $ reported amount for a financial disclosure for equity interest in a publicly traded company? $25,000 - ANSWhat is the $ reported amount for a financial disclosure for significant payments?

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+

Verified ANSWERS WITH RATIONALES 2025 |GRADED

A+